Home - MGC Pharma CBD Health

MXC: $0.023

Who

An EU pharmaceutical licensed company, MGC Pharmaceuticals Ltd (ASX: MXC) is an industry-leading, European biopharma company supplying GMP Phytocannabinoid derived medicines to patients globally.

With many years of real-world, technical and professional experience, MGC Pharma’s founders are all celebrated trailblazers in the Phytocannabinoid industry. MGC Pharma’s main objective is to create and supply superb Cannabinoid based pharmaceutical products for medical markets in North America, Europe, and Australasia.

Read More Read Edison Research On MGC

What

MGC Pharma creates premium phytocannabinoid-based pharmaceutical products from our GMP certified facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.

Using a unique labeling system across the range, MGC Pharma has made it simple to understand exactly what Genetic Materials are being utilized in each product. Within the range, each pharmaceutical solution offers a unique combination of cannabinoids in order to address different medical needs. You can learn about the benefits of each of the products below.

Where

Understanding that we work in an evolving industry which resonates worldwide, MGC Pharmaceuticals places high importance on global activities and supply chain. Unified supply and ability to function dynamically are essential. It permits our IP and experience to enable entry into new markets, helps with the growth of innovation investigation and research institutions (from the government to commercial to educational) and guarantees our products will seamlessly and reliably reach patients and customers, with the strictest QC and QA.

Why

We’re devoted to providing you with the latest company information. This comprises of ASX announcements, financial reports, and other significant updates. You can also access FAQs and see the latest share price information here. MGC Pharmaceuticals trades on the Australian Securities Exchange (ASX) under the ticker code MXC.

Why Invest

Latest ASX Announcements

28/9/20UPDATE ON ARTEMIC PHASE II TRIAL ON COVID-19 PATIENTS 21/9/20MXC WELCOMES NEW FCA GUIDANCE FOR CANNABIS SECTOR IN THE UK 15/9/20Issue of Securities - Appendix 2A 14/9/20MXC WELL POSITIONED FOR TGA DOWN-SCHEDULE OF CBD PRODUCTS

Why Phytocannabinoid-based medicines

Research Reports

Developed in partnership with prestigious universities, academia and pioneers in the industry, our publications set out the key challenges, risks and opportunities associated with establishing a national Medicinal Cannabis scheme in Australia.

17/2/20The Green Fund Research Report 8/10/19Alacrita Market Projections Report 10/7/19Edison Report 23/5/19Research Publication on the Effectiveness of Cannabinoids on Glioblastoma